Given that several MAPK pathway inhibitors are already in development for oncologic indications36, and that anti-cancer drug exposure has been linked to lower AD risk37, repositioning MLK3 inhibitors could represent a novel therapeutic strategy. This evidence concerns the gene MAP3K11 and cancer.